Wave Life Sciences Balance Sheet Health
Financial Health criteria checks 6/6
Wave Life Sciences has a total shareholder equity of $33.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $235.3M and $202.0M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$180.92m |
| Equity | US$33.26m |
| Total liabilities | US$202.01m |
| Total assets | US$235.27m |
Recent financial health updates
We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth
Apr 09
We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow
Sep 13Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely
Mar 30Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?
Aug 12Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?
Apr 21Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?
Jan 11Recent updates
We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth
Apr 09Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche
Mar 09Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues
Mar 03We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow
Sep 13Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially
May 08Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely
Mar 30Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?
Jan 20Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates
Nov 11Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?
Aug 12Wave Life Sciences Q2 2022 Earnings Preview
Aug 10Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?
Apr 21Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?
Jan 11We Think Wave Life Sciences (NASDAQ:WVE) Needs To Drive Business Growth Carefully
Sep 24What Does The Future Hold For Wave Life Sciences Ltd. (NASDAQ:WVE)? These Analysts Have Been Cutting Their Estimates
Aug 07Wave Life Sciences posts proof-of-concept data from genetic disorder study
Jun 02Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Slashed This Year's Estimates
May 15Things Look Grim For Wave Life Sciences Ltd. (NASDAQ:WVE) After Today's Downgrade
Apr 02Wave Life Sciences (NASDAQ:WVE) Share Prices Have Dropped 80% In The Last Three Years
Feb 19Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?
Jan 13
Financial Position Analysis
Short Term Liabilities: WVE's short term assets ($196.8M) exceed its short term liabilities ($165.9M).
Long Term Liabilities: WVE's short term assets ($196.8M) exceed its long term liabilities ($36.1M).
Debt to Equity History and Analysis
Debt Level: WVE is debt free.
Reducing Debt: WVE had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: WVE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: WVE has sufficient cash runway for 1.4 years if free cash flow continues to grow at historical rates of 6.1% each year.